SCHEMBL7913374

SCHEMBL7913374

CN(C)S(=O)(=O)c1cccc2c(N)cccc12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.59
NSD2 O96028 9/20 0.56
CA2 P00918 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
HTT P42858 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
HIF1A Q16665 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
EDNRA P25101 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29900497 1.00 TTR (0.59) TTRNSD2CA2TDP1HTT
SCHEMBL9276192 0.89 CHEK1 (0.48) TTRNSD2CA2TDP1HTT
SCHEMBL29212099 0.81 CYP1A2 (0.71) NSD2CA2TDP1HTTCYP1A2
SCHEMBL10877565 0.81 ALDH1A1 (0.47) TTRNSD2CA2HTTALDH1A1
Hydrochloric Acid SCHEMBL10867384 0.80 MCL1 (0.47) TTRNSD2CA2TDP1ALDH1A1
SCHEMBL30908488 0.80 GAA (0.58) CA2HTTALDH1A1SMN1; SMN2
SCHEMBL1439407 0.80 GAA (0.58) CA2HTTALDH1A1SMN1; SMN2
SCHEMBL7212515 0.79 CYP3A4 (0.48) TTRNSD2CA2HTTALDH1A1
SCHEMBL9927438 0.79 TTR (0.66) TTRNSD2CA2TDP1ALDH1A1
SCHEMBL13788915 0.78 TDP1 (0.54) TTRNSD2CA2TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001010890-A2 PROCESS OF SYNTHESIS OF FLUORESCENT PROTEASE SUBSTRATES CHEMRX ADVANCED TECHNOLOGIES, INC. (US) 2001-02-15 WO claimed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 US disclosed
US-11845724-B2 USP30 inhibitors and uses thereof VINCERE BIOSCIENCES, INC. (US) 2023-12-19 US disclosed
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2022-10-06 US disclosed
EP-4028385-A1 USP30 INHIBITORS AND USES THEREOF Vincere Biosciences, Inc. (US) 2022-07-20 EP disclosed
WO-2021050992-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. (US) 2021-03-18 WO disclosed
WO-2021050992-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. (US) 2021-03-18 WO disclosed
US-20090186829-A1 Nitrosation-Inducible Inhibitors Biological Macromolecules NEW YORK UNIVERSITY (US) 2009-07-23 US disclosed
US-20090186829-A1 Nitrosation-Inducible Inhibitors Biological Macromolecules NEW YORK UNIVERSITY (US) 2009-07-23 US disclosed
WO-2001010890-A2 PROCESS OF SYNTHESIS OF FLUORESCENT PROTEASE SUBSTRATES CHEMRX ADVANCED TECHNOLOGIES, INC. (US) 2001-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845724-B2 USP30 inhibitors and uses thereof USP30, USP28, USP1 TTR 3779/4885NSD2 1033/4885CA2 4601/4885
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 TTR 3779/4885NSD2 1033/4885CA2 4601/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 TTR 3779/4885NSD2 1033/4885CA2 4601/4885
US-20090186829-A1 Nitrosation-Inducible Inhibitors Biological Macromolecules NOS2, NOS1, NOS3 TTR 790/4885NSD2 1919/4885CA2 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.